Premium
Surfactant therapy improves pulmonary function in infants with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome
Author(s) -
Creery W. David,
Hashmi Aijaz,
Hutchison James S.,
Singh Ram N.
Publication year - 1997
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/(sici)1099-0496(199711)24:5<370::aid-ppul10>3.0.co;2-6
Subject(s) - ards , pneumocystis carinii , medicine , pneumonia , respiratory distress , pulmonary surfactant , respiratory disease , immunology , pulmonary function testing , lung , anesthesia , biology , biochemistry , pneumocystis jirovecii
Pneumocystis carinii pneumonia (PCP) is an important cause of acute respiratory failure in HIV‐infected children. PCP may initiate acute respiratory distress syndrome (ARDS) by adversely affecting surfactant physiology. We report improved pulmonary function following administration of bovine lipid extract surfactant to two infants with AIDS‐related PCP/ARDS. Pediatr. Pulmonol. 1997; 24:370–373. © 1997 Wiley‐Liss, Inc.